Loading...
Header Logo
Keywords
Last Name
Institution
 Back to Details

Connection

Peter Friedmann to Opioid-Related Disorders

This is a "connection" page, showing publications Peter Friedmann has written about Opioid-Related Disorders.

 
Connection Strength
  
 
 
5.021
  
  1. Friedmann PD, Wilson D, Knudsen HK, Ducharme LJ, Welsh WN, Frisman L, Knight K, Lin HJ, James A, Albizu-Garcia CE, Pankow J, Hall EA, Urbine TF, Abdel-Salam S, Duvall JL, Vocci FJ. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015 Mar; 50:50-8.
    View in: PubMed
    Score: 0.558
  2. Andrews CM, D'Aunno TA, Pollack HA, Friedmann PD. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev. 2014 Feb; 71(1):43-60.
    View in: PubMed
    Score: 0.519
  3. D'Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res. 2014 Feb; 49(1):230-48.
    View in: PubMed
    Score: 0.512
  4. Friedmann PD, Schwartz RP. Just call it "treatment". Addict Sci Clin Pract. 2012; 7:10.
    View in: PubMed
    Score: 0.475
  5. Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2010 Jul; 37(3):322-37.
    View in: PubMed
    Score: 0.380
  6. Stein MD, Friedmann PD. Optimizing opioid detoxification: rearranging deck chairs on the Titanic. J Addict Dis. 2007; 26(2):1-2.
    View in: PubMed
    Score: 0.326
  7. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005 Nov; 20(11):1038-41.
    View in: PubMed
    Score: 0.300
  8. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005 Sep; 82(3):411-9.
    View in: PubMed
    Score: 0.291
  9. McGarry KA, Stein MD, Clarke JG, Friedmann PD. Utilization of preventive health services by HIV-seronegative injection drug users. J Addict Dis. 2002; 21(2):93-102.
    View in: PubMed
    Score: 0.230
  10. Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP. Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. J Subst Abuse Treat. 2017 Oct; 81:66-72.
    View in: PubMed
    Score: 0.170
  11. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42.
    View in: PubMed
    Score: 0.155
  12. Mitchell SG, Willet J, Monico LB, James A, Rudes DS, Viglioni J, Schwartz RP, Gordon MS, Friedmann PD. Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016; 37(1):127-33.
    View in: PubMed
    Score: 0.152
  13. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7.
    View in: PubMed
    Score: 0.142
  14. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc (2003). 2013 May-Jun; 53(3):273-81.
    View in: PubMed
    Score: 0.126
  15. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013 Aug; 45(2):222-6.
    View in: PubMed
    Score: 0.125
  16. Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med. 2012 Sep; 6(3):179-85.
    View in: PubMed
    Score: 0.121
  17. McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, Rich JD. A randomized trial of methadone initiation prior to release from incarceration. Subst Abus. 2012; 33(1):19-29.
    View in: PubMed
    Score: 0.115
  18. Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012; 33(1):48-59.
    View in: PubMed
    Score: 0.115
  19. Cioe PA, Friedmann PD, Stein MD. Erectile dysfunction in opioid users: lack of association with serum testosterone. J Addict Dis. 2010 Oct; 29(4):455-60.
    View in: PubMed
    Score: 0.106
  20. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010 Sep; 39(2):157-66.
    View in: PubMed
    Score: 0.104
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.